ASRT vs. ORGO, VNDA, NLTX, VRCA, XERS, STTK, NKTX, EBS, SBTX, and ANRO
Should you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Organogenesis (ORGO), Vanda Pharmaceuticals (VNDA), Neoleukin Therapeutics (NLTX), Verrica Pharmaceuticals (VRCA), Xeris Biopharma (XERS), Shattuck Labs (STTK), Nkarta (NKTX), Emergent BioSolutions (EBS), Silverback Therapeutics (SBTX), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical preparations" industry.
Organogenesis (NASDAQ:ORGO) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
Organogenesis has a net margin of 1.34% compared to Organogenesis' net margin of -234.40%. Organogenesis' return on equity of 10.80% beat Assertio's return on equity.
Organogenesis has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Assertio has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.
49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 34.0% of Organogenesis shares are owned by company insiders. Comparatively, 3.2% of Assertio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Assertio had 4 more articles in the media than Organogenesis. MarketBeat recorded 7 mentions for Assertio and 3 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.20 beat Assertio's score of 0.98 indicating that Assertio is being referred to more favorably in the news media.
Organogenesis presently has a consensus target price of $4.83, suggesting a potential upside of 75.76%. Assertio has a consensus target price of $4.58, suggesting a potential upside of 362.36%. Given Organogenesis' stronger consensus rating and higher probable upside, analysts plainly believe Assertio is more favorable than Organogenesis.
Organogenesis has higher revenue and earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
Assertio received 9 more outperform votes than Organogenesis when rated by MarketBeat users. However, 66.21% of users gave Organogenesis an outperform vote while only 58.99% of users gave Assertio an outperform vote.
Summary
Organogenesis beats Assertio on 10 of the 17 factors compared between the two stocks.
Get Assertio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assertio Competitors List
Related Companies and Tools
